Clinical Trials Directory

A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

This study is to evaluate the pharmacokinetics, pharmacodynamics, and safety of single and multiple doses of armodafinil (50, 100, and 150 mg/day) in children and adolescents with excessive sleepiness associated with narcolepsy.

Stanford is now accepting new patients for this trial. Please contact Paul Stowers at 650-721-7551 for more information.



  • drug : Armodafinil

Phase: Phase 1


Ages Eligible For Study:

6 Years - 17 Years

Inclusion Criteria

- Written informed consent is obtained from each patient's parent or legal guardian and written assent is obtained from each patient. - The patient is a male or female 6 through 17 years of age with a body mass index (BMI) equal to or greater than 10th percentile for age and gender, inclusive. - The patient has a diagnosis of narcolepsy with cataplexy or narcolepsy without cataplexy according to the criteria established by the International Classification of Sleep Disorders (ICSD)-2 for narcolepsy.

External Links

Explore related trials

Contact information

Primary Contact:

Paul Stowers 650-721-7551

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: